By integrating morphological, ultrastructural, and signaling data, this study establishes a reproducible agarose-microwell platform for investigating architecture-dependent receptor regulation and offers a robust platform for future preclinical studies on drug response and targeted delivery in HER2+ breast cancer. Here, ERBB2 is linked to breast cancer.